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ABSTRACT
Metabolic syndrome (MS) is a clustering of cardiovascular disease 
risk factors. It is a major health challenge globally, with an increased 
prevalence in the developing world. Studies on its role on reproduction 
in Nigeria are currently sparse. This article therefore, examines 
current knowledge on metabolic syndrome and reproduction in 
Nigerians. Academic databases including PubMed as well as Google 
search engine were searched between 2012 and 2019 for metabolic 
syndrome in reproduction in Nigerian males and females. Current 
observations suggest that metabolic syndrome adversely affects 
reproduction. 
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INTRODUCTION
Metabolic syndrome (MS) is a multi-factorial endo-
crinopathy framed by classical cardiovascular risk 
factors such as insulin resistance, hyperglycaemia, 
abdominal obesity, pro-inflammatory state, essen-
tial hypertension and dyslipidaemia.1 The National 
Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III) defined MS as the pres-
ence of at least three of the following clinical criteria: 
waist circumference (>88 cm in women, > 94 cm in 
men), high density lipoprotein- cholesterol (HDL-
C) <50 mg/dl, blood pressure ≥130/85 mmHg, 
fasting plasma glucose ≥110 mg/dl, triglyceride 
>150 mg/dl.2 The presence of a component of MS 
increases the risk of future development of MS, 
therefore early detection of MS components could 
lead to targeted interventions.3
The International Diabetes Federation (IDF) 
estimates that approximately 25% of the world’s 
population has MS.4 This estimate however varies 
due to age, gender and ethnicity.5 In Nigeria, MS 
affects about 33.1% of the population, thus predis-
posing them to cardiovascular disease (CVD). 
6This increased prevalence has been attributed to 
the adoption of western lifestyle which is marked 
by reduced physical activity and substitution 
of the traditional African diet rich in fruits and 
vegetables for the energy-laden foods.7 Elevated 
waist circumference, reduced HDL-C and high 
blood pressure are prevalent MS components in 
Nigerians, however, with gender differences.8 In a 
Nigerian study, elevated waist circumference was 
more frequent in females while reduced HDL-C 
was more frequent in males.8
MS is more common in Nigerian females with 
type-2 diabetes mellitus (DM 2) compared with 
males.9 This is a sharp contrast to reports from the 
United States that showed a higher prevalence in 
white males than females.10 MS is known to increase 
with age.8 A Nigerian study observed 72.5% of the 
study participants aged 50 years and above compared 
with 27.5% that were aged less than 50 years.9 This 
has been attributed to the involvement of aging in 
different pathologies. Aging is associated with insu-
lin resistance and increased visceral adiposity which 
are important in the pathogenesis of MS.9
The role of metabolic syndrome in reproduction 
has not been adequately studied in Nigerians. This 
review is therefore aimed at discussing the relation-
ship of MS with reproduction in Nigerian males 
and females. This may lead to improvement in the 
management of these conditions thus, improving 
quality of life. 
METHODOLOGY 
Academic databases particularly PubMed and 
Google search engines were searched between 2012 
and 2019 for studies on MS and reproduction in 
Nigeria using expressions such as ‘MS and male 
infertility in Nigeria’, ‘MS and female infertility in 
Nigeria’, 
MS, Male Sexual Function and Infertility 
MS is characterized with male and female infertility 
with male factor infertility present in 20-50% of 
couples either independently of or in conjunction 
with female factor.11 In Nigeria, male factor infertil-
ity has a prevalence of about 40%.12
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The male sexual function is an intricate, 
multi-component biologic process that involves 
mechanisms for the regulation of libido, arousabil-
ity, penile tumescence, rigidity, orgasm, ejacula-
tion and sexual satisfaction. Testosterone plays an 
important role in these mechanisms.13,14 Androgen-
deficient men have decreased overall sexual activity. 
15 Low levels of total and free testosterone as well as 
sex hormone-binding globulin (SHBG) are peculiar 
to males with MS and DM 2. Hypogonadism char-
acterized by diminished libido, erectile dysfunction 
and poor nocturnal and early morning erection 
was found in 20-38% and 46-55% of men with MS 
and DM 2 respectively in a Nigerian study.16 This 
indicates a higher prevalence of hypogonadism in 
Nigeria than previously thought. Moreover, risk 
factors of CVD; obesity (general and central) as 
well as dyslipidaemia showed a strong correlation 
with hypogonadism in another Nigerian study.17
Obesity interferes with the  hypothalamic- 
pituitary-gonadal axis which could result in hypo-
gonadism.18 Hypogonadotropic hypogonadism 
results from testicular deficit, hence, impaired 
spermatogenesis and low testosterone level. 
Hypergonadotropic hypogonadism emanates 
from the insufficiency at the hypothalamus and 
or pituitary gland. This results in low secretion 
of luteinizing hormone (LH) and FSH as well as 
reduced stimulation of the leydig cells to secrete 
testosterone.18
Dysglycaemia, dyslipidaemia and obesity are 
capable of inducing oxidative stress in the testicu-
lar microenvironment. This could result in sperm 
plasma membrane damage with nuclear/mitochon-
drial DNA fragmentation occurring in response 
to reactive oxygen species (ROS) generation. 
Decreased ATP synthesis and systemic inflam-
mation can also contribute to increased sperm 
nuclear DNA (nDNA) fragmentation in MS. This 
contributes to decreased fertility in males with 
MS.1,19 Furthermore, high scrotal temperature, 
sleep apnea, increased adipokines and adipose-de-
rived hormones are consequences of obesity that 
adversely affect male fertility by interrupting 
spermatogenesis.19
MS and Female Infertility
Infertility, defined as failure to conceive after 
unprotected regular sexual intercourse for two 
years in the absence of known reproductive pathol-
ogy, affects about 10% of married couples in Africa, 
with sub-Saharan Africa having the highest prev-
alence.20,21,22,23 MS is associated with disorders of 
female reproduction, high incidence of menstrual 
dysfunction, anovulation and infertility in obese 
women of reproductive age.24 
Delay in spontaneous conception was observed 
in Nigerian obese women. A 5% reduction in the 
probability of achieving pregnancy for every unit 
of BMI exceeding 29 kg/m2 was also observed. 
Oligomenorrhea and hypomenorrhea were asso-
ciated with obesity in the study population.25 
This could be due to defective folliculogene-
sis.26 Hyperinsulinaemia, a typical feature of MS 
inhibits folliculogenesis thus, decreasing fertil-
ity in obese women.27 Another Nigerian study 
found a significantly elevated LH and prolactin 
as well as significantly reduced progesterone and 
oestradiol in infertile women compared to fertile 
women.28
MS and Preeclampsia
Preeclampsia is diagnosed when a pregnant woman 
develops hypertension and significant proteinuria 
after 20 weeks gestation.29 The pathophysiology of 
preeclampsia is still a subject of much speculation, 
it is however, thought to involve defective placental 
development.30 Defective invasion of the maternal 
spiral arteries in the deciduas and myometrium by 
foetal cytotrophoblasts results in reduced uterine 
perfusion and placental ischaemia which induces 
the release of bioactive factors that mediate the 
pathology of preeclampsia.31 This could result/
culminate in intrauterine growth restriction or 
death.32
Preeclampsia is a leading cause of maternal 
morbidity and mortality. A lot of people are unaware 
of its danger signs and complications.33 In Nigeria, 
its prevalence ranges from 2% and 16.7%.34,35 
Maternal obesity increases the risk of preeclampsia. 
BMI at first visit to antenatal clinic ≥25 kg/m2 and 
previous history of preeclampsia are its major risk 
factors in a Nigerian study.36 Furthermore, over-
weight or obese women at 20 weeks gestation are 
about 4 fold increased risk when compared with 
normal weight women.36
In another Nigerian study, C-reactive protein 
and fibrinogen were associated with preeclampsia.37 
Obesity is a subclinical inflammatory state in which 
there is an increased production of interleulin-6 
that stimulates C-reactive protein which promotes 
insulin resistance and CVD complications.38 
Elevated serum triglycerides and total cholesterol 
as well as lower HDL levels were reported in women 
with preeclampsia in Nigeria. This could be a sign 
of comprised vascular function.39 
Copeptin, a 39-amino acid peptide was 
reported as a reliable predictor of preeclampsia in a 
Nigerian study and may distinguish between severe 
preeclampsia and mild preeclampsia.40 A recent 
study in Egypt suggested it as a possible marker of 
obesity- induced insulin resistance.41 
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An American study showed that preeclampsia 
is characterized by increased insulin resistance, 
hypertriglyceridemia, low high-density lipoprotein 
cholesterol, high low-density lipoprotein choles-
terol, and high maternal and foetal plasma amino 
acid concentrations.42 It is therefore believed that 
preeclampsia is a case of MS occurring in pregnancy. 
MS and Polycystic ovary syndrome 
Polycystic ovarian syndrome (PCOS) is a major 
endocrinopathy among women of reproductive 
age and constitutes a major health and economic 
burden.43 It confers a substantially increased risk 
for DM 2.44 Its prevalence of between 12.2 and 
27.6% has been reported in Nigeria using different 
criteria.45,46,47 Polycystic ovarian syndrome is char-
acterized by menstrual irregularities, hyperandro-
genism and infertility.48,49 Issues of MS in women 
with PCOS have generated tremendous interest.50 
Features such as insulin resistance and hyperinsuli-
naemia are common to women with MS and PCOS. 
51 Reports showed that PCOS increases the risk of 
MS.52,53 
Dysglycaemia is common in Nigerian women 
with PCOS, particularly those with higher serum 
testosterone levels.54 Obese women with PCOS were 
reported to have significantly high plasma glucose, 
total cholesterol, triglyceride, low density lipopro-
tein but lower level of high density lipoprotein.55 
The pathogenicity of elevated BMI (overweight 
and obesity) in PCOS is attributed to reduction in 
cholecystokinin secretion, dysregulation of ghrelin, 
increased level of neuropeptide Y and androgens. 
These could enhance insulin resistance, a peculiar 
feature of MS.55
Insulin resistance is attributed to a post binding 
defect in receptor signaling as a result of increased 
receptor substrate-1 serine phosphorylation that 
selectively affects metabolic pathways in classic 
insulin target tissues and the ovary. Insulin func-
tions as a co-gonadotropin by its ability to modu-
late ovarian steroidogenesis. The genetic disruption 
of insulin signaling in the brain suggests its impor-
tance in ovulation and body weight regulation.44 
Hyperinsulineamia amplifies LH action on theca 
cells, increases androgen levels and reduces SHBG 
levels.56,57,58 Hyperandrogenism and hyperinsuli-
naemia impair follicle development thus, adversely 
affecting fecundity.59
CONCLUSION 
Observations from this study show that metabolic 
syndrome adversely affect reproduction. Healthy 
lifestyle and diet should be adopted to reduce the 
incidence of metabolic syndrome. This will go a 
long way in improving human reproduction.
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